相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
Robert A. Hauser et al.
LANCET NEUROLOGY (2011)
Initiating Levodopa/Carbidopa Therapy With and Without Entacapone in Early Parkinson Disease The STRIDE-PD Study
Fabrizio Stocchi et al.
ANNALS OF NEUROLOGY (2010)
Continuous Dopaminergic Therapy in Parkinson Disease: Time to Stride Back?
A. Jon Stoessl
ANNALS OF NEUROLOGY (2010)
Double-Blind Study of Pardoprunox, a New Partial Dopamine Agonist, in Early Parkinson's Disease
Juliana Bronzova et al.
MOVEMENT DISORDERS (2010)
Task Force Report on Scales to Assess Dyskinesia in Parkinson's Disease: Critique and Recommendations
Carlo Colosimo et al.
MOVEMENT DISORDERS (2010)
Long-Term Antidyskinetic Efficacy of Amantadine in Parkinson's Disease
Elisabeth Wolf et al.
MOVEMENT DISORDERS (2010)
Age of Parkinson's Disease Onset as a Predictor for the Development of Dyskinesia
Stephen Ku et al.
MOVEMENT DISORDERS (2010)
Onset of Dyskinesia with Adjunct Ropinirole Prolonged-Release or Additional Levodopa in Early Parkinson's Disease
Ray L. Watts et al.
MOVEMENT DISORDERS (2010)
Dyskinesia and the antiparkinsonian response always temporally coincide A retrospective study
John G. Nutt et al.
NEUROLOGY (2010)
Long-term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
ARCHIVES OF NEUROLOGY (2009)
Multiple roles for nicotine in Parkinson's disease
Maryka Quik et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Safety and Tolerability of Pardoprunox, a New Partial Dopamine Agonist, in a Randomized, Controlled Study of Patients with Advanced Parkinson's Disease
R. A. Hauser et al.
EUROPEAN NEUROLOGY (2009)
Patient Profile, Indications, Efficacy and Safety of Duodenal Levodopa Infusion in Advanced Parkinson's Disease
David Devos
MOVEMENT DISORDERS (2009)
Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease
Angelo Antonini et al.
PARKINSONISM & RELATED DISORDERS (2009)
Priming for L-dopa-induced dyskinesia in Parkinson's disease: A feature inherent to the treatment or the disease?
Agnes Nadjar et al.
PROGRESS IN NEUROBIOLOGY (2009)
Continuous jejunal levodopa infusion in patients with advanced Parkinson disease:: Practical aspects and outcome of motor and non-motor complications
Karla Eggert et al.
CLINICAL NEUROPHARMACOLOGY (2008)
Molecular mechanisms underlying levodopa-induced dyskinesia
Paolo Calabresi et al.
MOVEMENT DISORDERS (2008)
Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study
Pedro J. Garcia Ruiz et al.
MOVEMENT DISORDERS (2008)
Nicotine and Parkinson's disease: Implications for therapy
Maryka Quik et al.
MOVEMENT DISORDERS (2008)
Molecular mechanisms of L-DOPA-induced dyskinesia
Peter Jenner
NATURE REVIEWS NEUROSCIENCE (2008)
Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
Robert A. Hauser et al.
MOVEMENT DISORDERS (2007)
Continuous dopaminergic stimulation - From theory to clinical practice
Angelo Antonini
PARKINSONISM & RELATED DISORDERS (2007)
Levodopa-induced dyskinesias
Giovanni Fabbrini et al.
MOVEMENT DISORDERS (2007)
Impact of pramipexole on the onset of levodopa-related dyskinesias
Radu Constantinescu et al.
MOVEMENT DISORDERS (2007)
Pooled analysis of tobacco use and risk of Parkinson disease
Beate Ritz et al.
ARCHIVES OF NEUROLOGY (2007)
L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment
M. Angela Cenci
PARKINSONISM & RELATED DISORDERS (2007)
Kinetic-dynamic monitoring of levetiracetam effects in patients with Parkinson disease and levodopa-induced dyskinesias
Manuela Contin et al.
CLINICAL NEUROPHARMACOLOGY (2007)
Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease
Robert A. Hauser et al.
ARCHIVES OF NEUROLOGY (2006)
Development of dyskinesias in a 5-year trial of ropinirole and L-dopa
Olivier Rascol et al.
MOVEMENT DISORDERS (2006)
Low frequency rTMS of the SMA transiently ameliorates peak-dose LID in Parkinson's disease
Livia Brusa et al.
CLINICAL NEUROPHYSIOLOGY (2006)
Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease
Warren Olanow et al.
NATURE CLINICAL PRACTICE NEUROLOGY (2006)
Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia
KE Lyons et al.
CLINICAL NEUROPHARMACOLOGY (2006)
Practice parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology
R Pahwa et al.
NEUROLOGY (2006)
A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia
F Gardoni et al.
JOURNAL OF NEUROSCIENCE (2006)
Non-invasive brain stimulation for Parkinson's disease: a systematic review and meta-analysis of the literature
F Fregni et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2005)
Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease
TA Zesiewicz et al.
MOVEMENT DISORDERS (2005)
Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease - A clinical and pharmacokinetic study
F Stocchi et al.
ARCHIVES OF NEUROLOGY (2005)
Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy
L Mazzella et al.
PARKINSONISM & RELATED DISORDERS (2005)
Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations
J Jankovic
MOVEMENT DISORDERS (2005)
Continuous subcutaneous apomorphine therapy improves Dyskinesias in Parkinson's disease: A prospective study using single-dose challenges
R Katzenschlager et al.
MOVEMENT DISORDERS (2005)
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs
S Miyamoto et al.
MOLECULAR PSYCHIATRY (2005)
Clozapine improves dyskinesias in Parkinson disease - A double-blind, placebo-controlled study
F Durif et al.
NEUROLOGY (2004)
Improvement of motor function in early Parkinson disease by safinamide
F Stocchi et al.
NEUROLOGY (2004)
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
BA Lynch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Smoking and Parkinson's disease: Systematic review of prospective studies
MF Allam et al.
MOVEMENT DISORDERS (2004)
Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in Parkinsonian monkeys
N Bélanger et al.
MOVEMENT DISORDERS (2003)
Noradrenergic drugs for levodopa-induced dyskinesia
C Colosimo et al.
CLINICAL NEUROPHARMACOLOGY (2003)
Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease
JM Savola et al.
MOVEMENT DISORDERS (2003)
Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long-term follow-up study of 64 patients
AJ Manson et al.
MOVEMENT DISORDERS (2002)
Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease
F Stocchi et al.
BRAIN (2002)
Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up
P Kanovsky et al.
MOVEMENT DISORDERS (2002)
Duodenal levodopa infusion in Parkinson's disease - long-term experience
D Nilsson et al.
ACTA NEUROLOGICA SCANDINAVICA (2001)
Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
JE Ahlskog et al.
MOVEMENT DISORDERS (2001)
Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results
F Stocchi et al.
NEUROLOGICAL SCIENCES (2001)
Pramipexole vs levodopa as initial treatment for Parkinson disease - A randomized controlled trial
R Holloway et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
O Rascol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: A double-blind, placebo-controlled study
BJ Snow et al.
CLINICAL NEUROPHARMACOLOGY (2000)
分享论文
